Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam

Psychopharmacology

Volumn 150, Issue 2, 2000, Pages 185-190

  Yasui, Norio ^a   Kondo, Tsuyoshi ^a   Furukori, Hanako ^a   Kaneko, Sunao ^a   Ohkubo, Tadashi ^b   Uno, Tsukasa ^b   Osanai, Takako ^b   Sugawara, Kazunobu ^b   Otani, Koichi ^c  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

Alprazolam; Bioavailability; Cytochrome P450 3A4; Grapefruit juice

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 3A4; WATER;

ADULT; ANXIETY NEUROSIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME INHIBITION; FEMALE; FOOD DRUG INTERACTION; FRUIT JUICE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BEVERAGES; CITRUS; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PSYCHOMOTOR PERFORMANCE; SMOKING; STATISTICS, NONPARAMETRIC;

EID: 0033919766     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000438     Document Type: Article

References (36)

1. Ameer B, Weintraub RA (1997) Drug interactions with grapefruit juice. Clin Pharmacokinet 33:103-121
2. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). American Psychiatric Association, Washington DC
3. Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD (1996) Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 60:25-33
4. Bock KW, Schrenk D, Forster A, Griese E-U, Morike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209-228
5. Eagling VA, Profit L, Back DJ (1999) Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol 48:543-552
6. Edward DJ, Bernier SM (1996) Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 59:1025-1030
7. Edward DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P (1999) 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 65:237-244
8. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y (1997) Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391-396
9. Furukori H, Otani K, Yasui N, Kondo T, Kaneko S, Shimoyama R, Ohkubo T, Nagasaki T, Sugawara K (1998) Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 18:364-369
10. Garzone PD, Kroboth PD (1989) Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 16:337-364
11. Greenblatt DJ, Wright CE (1993) Clinical pharmacokinetics of alprazolam: therapeutic implications. Clin Pharmacokinet 24:453-471
12. Greenblatt DJ, Shader RI, Harmatz JS, Franke K, Koch-Weser J (1977) Absorption rate, blood concentrations, and early response to oral chlordiazepoxide. Am J Psychiatry 134:559-562
13. Greenblatt DJ, Harmatz JS, Shader RI (1993) Plasma alprazolam concentrations: relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 50:715-722
14. Guengerich FP, Kim DH (1990) In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenetics 11:2275-2279
15. Guy W (1976) Clinical global impressions. In: ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, Rockville, MD, pp 218-222
16. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF (1998) Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 11:252-259
17. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ (1995) Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 58:127-131
18. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259
19. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S (1995) Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20-28
20. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76[Suppl 334]:11-100
21. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955
22. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB (1997a) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553
23. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon K, Schmiedln-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB (1997b) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260
24. Lundahl JUE, Regardth CG, Edgar B, Johnsson G (1998) The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol 54:75-81
25. Nagasaki T, Ohkubo T, Sugawara K, Yasui N, Otani K, Kaneko S (1997) Determination of alprazolam and α-hydroxyalprazolam in plasma by high-performance liquid chromatography. Anal Sci 13:245-249
26. Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Hayashi K, Chiba K, Ishizaki T (1997) Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam. Neuropsychopharmacology 16:8-14
27. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents -decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25:1228-1233
28. Shimada T, Yamazaki H, Miura M, Inui Y, Guengerich FP (1994) Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423
29. Takanaga H, Ohnishi A, Matsuo H, Murakami H, Sata H, Kuroda K, Urae A, Higuchi S, Sawada Y (2000) Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 49:49-58
30. Vanakoski J, Mattila MJ, Seppälä T (1996) Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol 50:501-508
31. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI (1998) Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol 18:256
32. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994) Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31
33. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184
34. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharmacol 24:475-490
35. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T (1996) A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 59:514-519
36. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K (1998) Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 139:269-273